No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue ...

Ultimately, medication non-adherence costs lives, drives up costs – and there's real-world evidence that shows it contributes to COVID-19 hospitalisations, Rose says.